Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Enterovirus 71 vaccine: close but still far

Dingmei Zhang, Jiayuan Lu, Jiahai Lu

5. INTRODUCTION

Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-polioymyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field.

SUMMARY

Background: Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-polioymyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field.

Methods: Fifty-five articles on EV71 vaccine development, published from 1974 to 2009, were collected from Sun Yat-sen University library and reviewed.

Results: Various types of vaccine have been developed for EV71. In results published to date, all vaccines for EV71 under development appear to elicit an immune response in rodents or in monkeys. According to the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated virus in order to meet the immediate demands for EV71 control. With regard to the attenuated vaccine, it is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is another promising vaccine candidate for EV71, but needs further development. The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope vaccine; these remain viable potential vaccine strategies worthy of further study and development.

Conclusions: The conservation of the three-dimensional structure is important for the EV71 inactivated vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered.

© 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

EV71 possesses a single-stranded RNA genome of approximately 7500 nucleotides, consisting of a single open reading frame (ORF) flanked by 5'-untranslated regions (5'UTR) and 3'-untranslated regions (3'UTR). The ORF is expressed as a large polyprotein that can be cleaved into P1, P2, and P3 regions. The P1 region encodes four structural proteins VP1, VP2, VP3, and VP4. The P2 and P3 regions encode nonstructural proteins, such as proteases 2A, 2B, and 3CD, responsible for virus replication and virulence. Protease 2A autocatalytically cleaves P1 at its N-terminus and liberates P1 from the nascent polyprotein. While protease 3CD cleaves the P1 precursor into VP1, VP3 and VP0 (VP2 and VP4). These three structural proteins spontaneously assemble and form the crystalline virus-like particles.

Though there has been a significant increase in EV71 epidemic activity throughout the Asia-Pacific region, effective antiviral therapies and vaccines have, to-date, not been available. The development of effective vaccines is a top priority in terms of control strategies. Below is an overview of the field of EV71 vaccine preparation to date.

1. INTRODUCTION

Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is the most frequently detected pathogen in hand-foot-and-mouth disease (HFMD) patients complicated with neurological dysfunction. EV71 was first isolated in California in 1969, and its association with HFMD was verified in 1974. It was later confirmed as the causative agent responsible for HFMD outbreaks in Hungary, Australia, Hong Kong, Taiwan, Japan, and Singapore. Moreover, in 2008 and 2009, a large outbreak occurred in Mainland China. Children under 5 years of age have been found to be particularly susceptible to the severest form of EV71-associated neurological disease. This is an important public health problem causing serious clinical illness and, potentially, death in young children.
2. Inactivated virus vaccine

As conventional vaccines, inactivated virus vaccines, such as inactivated influenza vaccine and inactivated hepatitis A vaccine, have been successfully used in the human. Sero-epidemiologic studies have indicated that the preexisting neutralizing antibody to EV71 is protective against the severe outcomes of infection. Yu et al. and Wu et al. showed that passive transfer of serum from formalin-inactivated and heat-inactivated virus vaccine immunized adult mice, could provide protection against EV71 infection in neonatal mice; meanwhile, maternal immunization with inactivated EV71 vaccine was able to prolong the survival of suckling mice after EV71 lethal challenge. These results show the value of the inactivated virus vaccine for the effective control of EV71. However, the conservation of the three-dimensional structure is important in order to induce a strong immune response. Therefore, for the heat-inactivated virus, a much higher dose of viral antigen and adjuvant are required to achieve an acceptable level of immunogenicity and protection.

Obviously, an ideal vaccine strain is required for the large-scale preparation of the inactivated EV71 vaccine, as has been the case for the Sabin oral polio vaccine (OPV) strain. Lin et al. developed an EV71 strain, YN3-4a, exhibiting a rapid growth rate in Vero cells with a larger plaque size and a higher lethal dose (LD<sub>50</sub>) in newborn mice. Lin and coworkers showed that mouse antiserum raised against YN3-4a was able to neutralize a broad range of EV71 strains isolated from patients of a variety of geographic origins at different points in time. YN3-4a possesses desirable features, such as a high viral yield, the ability to propagate in serum-free medium, and strong immunogenicity, as well as broad-based antigenic coverage and passage stability, indicating its potential for development as an inactivated vaccine strain.

A powerful cell system is also important in the development of an inactivated vaccine. As shown by Wu and coworkers, a serum-free Vero cell culture with a 5 g/l Cytodex 1 microcarrier concentration in a 2-l bioreactor has also been established, yielding a high titer of 5.8 × 10<sup>7</sup> TCID<sub>50</sub>/ml EV71 production. On the basis of the study of Wu et al., Liu et al. showed that the serum-free culture increased post-infection cell death and reduced the virus productivity, but elicited a higher neutralizing antibody titer in immunized mice as compared to the serum-containing cultures. Therefore, the serum-free microcarrier culture is a valuable technique for developing inactivated EV71 vaccines on a large scale.

3. Attenuated strain vaccine

An example of a successful attenuated strain vaccine is Sabin OPV. This was introduced in the early 1960s due to its easier administration, lower cost, and higher intestinal mucosal immunity than the inactivated polio vaccine (IPV), and has since been approved for worldwide application for polio eradication. Because of the similarities between poliovirus and EV71, Arita et al. have developed an EV71 attenuated strain, EV71 (S1-3'), carrying mutations in the 5'UTR, 3D polymerase (3D<sup>pol</sup>) and 3'UTR 5' non-translated based on the attenuation determinants of poliovirus. This EV71 (S1-3') strain is characterized by attenuated neurovirulence and limited spread of virus. In a subsequent study by Arita et al., three cynomolgus monkeys were inoculated with EV71 (S1-3'), followed by a lethal challenge with the parental virulent strain EV71 (BrCr-TR); they suffered mild neurological symptoms (tremor), but survived the lethal challenge without exacerbation of the symptoms. Moreover, the sera from the immunized monkeys showed a broad spectrum of neutralizing activities against different genotypes of EV71. These findings indicate that EV71 (S1-3') acts as an effective antigen.

However, it does cause mild neurological symptoms when inoculated via the intravenous route. Additional studies are required to ensure that further attenuation produces effective attenuated vaccine strains. EV71 infection via the oral route did not efficiently cause neurological disorders in the inoculated monkeys. Therefore the cynomolgus monkeys were inoculated by intravenous route instead of the oral route to evaluate the antigenicity of the attenuated EV71 vaccine. Thus, to develop an oral EV71 attenuated vaccine, a valid animal model of EV71 infection by the oral route is urgently needed.

Meanwhile, it is well known that in a small number of OPV recipients and their close contacts, especially those with primary humoral immunodeficiencies, the vaccine strain can mutate to a neurovirulent strain during OPV replication and cause vaccine-associated paralytic poliomyelitis (VAPP), which is an adverse side effect of OPV. A 1969 World Health Organization Collaborative study found that the VAPP rate was one in every 5.9 million doses administered for vaccine recipients and one in every 6.7 million doses administered for contacts. Therefore, the genetic stability of the attenuated OPV is a major concern, and efforts should be made to further attenuate the neurotoxic effects and increase the genetic stability of the attenuated EV71 vaccine before clinical use.

4. Subunit vaccine

To overcome the potential problem of reversion to virulence of attenuated strain vaccine, subunit vaccines consisting of only one or a few 'subunit' proteins of the pathogen that can stimulate immune responses directed at the intact virus have been developed using recombinant DNA technology. In common with other enteroviruses, the VP1, VP2, and VP3 of EV71 are responsible for the antigenic diversity of enteroviruses, but the VP1, the major capsid protein of EV71, is clustered with neutralization epitopes and has the potential to act as an antiviral subunit vaccine.

Wu et al. have described a recombinant VP1 protein expressed in Escherichia coli BL21, showing that the VP1 protein with a complete adjuvant is able to elicit a neutralizing antibody response, enhance T helper cell proliferation, and induce high levels of interleukin (IL)-10 and interferon (IFN)-γ in mice, providing direct evidence that the VP1 protein contains neutralizing epitopes independent of other viral capsid proteins; this paves the way for the use of VP1 as a backbone antigen for developing subunit vaccines against EV71.

Transgenic edible plants and mammalian glands are possible alternatives to prokaryotic and eukaryotic cell culture systems, offering a palatable oral delivery system, which can elicit a good mucosal immune response as well as systemic humoral and cellular immune responses, making it particularly suitable for protecting against infectious agents intruding via the mucosal surface. EV71 initiates disease following implantation in the gut mucosa, showing the potential of an oral vaccine for immunization against EV71 infection. Chen and colleagues have developed VP1-expressing transgenic tomato fruits. These were used as a mouse free-feeding oral vaccine. The VP1-specific fecal IgA and serum IgG were then observed in mice, and both humoral and cellular immunity against EV71 were established, showing the potential use of the transgenic tomato as an oral vaccine. Meanwhile, other EV71 oral VP1 vaccine delivery systems, such as milk of transgenic mice described by Chen et al. and the Salmonella-based method by Chiu et al. have been extensively explored.

For oral vaccines, gastric acid and enzymatic digestion are major concerns, since they may interfere with vaccine absorption. The Enterovirus genus can withstand human gastric acid and remain infectious below pH 3.0. However, VP1 is a capsid protein on the surface of the EV71 particle, and whether it can resist
human gastric acid has not been fully addressed. Meanwhile, digestive enzymes may also degrade the antigens. In the experiment of Chen et al., mice gavaged with VP1 protein produced more VP1-specific antibodies than mice fed transgenic tomato containing more VP1 protein, in both sera and feces, indicating that chewing and digestion cause degradation of VP1 antigen. Also, the oral rotavirus VP4 protein vaccine has been shown to provide lower levels of antibodies and less protection than immunization by injection of the rotavirus VP4 protein, indicating the possible interference of digestive enzymes. Moreover, it has been difficult to determine the precise dose of antigens for immunization, since competition with food and microbial antigens interferes with the absorption rate of vaccine components. Therefore, to improve oral vaccine delivery, many strategies have been developed, such as using tissue-specific promoters, the addition of mucosal immune adjuvant, using liposomes to protect the fusion peptides in the phospholipid bilayer vesicles from the gastric enzymes, and N-trimethyl chitosan nanoparticles. For the oral EV71 VP1 subunit vaccine, exploring strategies to protect antigens from enzyme degradation in the gut is necessary.

5. DNA vaccine

DNA vaccines are expressed intracellularly in the same manner as during natural viral infection and can stimulate either humoral immunity, cellular immunity, or both. Also, DNA vaccines only deliver the target subunit antigen and thus cause fewer adverse effects, making them another valuable vaccine choice for most viral infections.

Tung and co-workers developed an EV71 DNA vaccine by inserting the VP1 gene into a eukaryotic expression vector and evaluated the immune response in mice. Their study results showed that the anti-VP1 IgG level increased in mice immunized with DNA vaccine; in contrast, this level declined after boosting immunization. Furthermore, although the anti-VP1 IgG exhibited neutralizing activity against EV71, the neutralizing effect of the sera of mice immunized with the VP1 DNA vaccine was much lower than that of EV71-infected human serum. Another DNA vaccine developed by Wu et al. elicited a high neutralization titer and stable titer level, which could be detected even at a late post-immunization time. However, because the DNA vaccine contains fewer antigenic epitopes, it induces a weaker immune stimulation than the whole virus particles. Therefore, strategies to increase the immune stimulation ability of DNA vaccines have been developed including: incorporation of immunostimulatory sequences in the backbone of the plasmid, co-expression of stimulatory molecules, use of localization/secretory signals, and an appropriate delivery system, as well as adjuvants and optimization of transgene expression. All these techniques can help to prepare a better EV71 DNA vaccine.

6. Epitope peptide vaccine

An epitope peptide vaccine consisting of a well-defined immunogenic epitope stimulates an effective and specific protective immune response while avoiding potential undesirable effects.

The host immune response developed upon any viral infection is primarily CD4+ T cell-dependent, including the induction of a cytotoxic cellular response and efficient antibody response. Thus, identification of CD4+ T cell epitopes and B cell epitopes is of great importance in the design of effective epitope peptide vaccines. Foo and colleagues have published several studies aimed at identifying the T-cell and B-cell epitopes of EV71. In these studies, they identified three regions, 66–77, 145–159, and 247–261, spanning amino acids of the VP1 protein; they showed that these three regions could induce proliferation of CD4+ T cells, then producing abundant IL-2 and IFN-γ upon stimulation. Additionally, among the three peptides, amino acids 145–159 induced the strongest proliferative response and highest cytokine production. Furthermore, in order to identify the neutralizing linear epitopes, 95 overlapping synthetic peptides spanning the VP1 capsid protein of EV71 were used to immunize mice. Peptides containing amino acids 163–177 and 208–222 of VP1 protein were capable of eliciting neutralizing antibodies against EV71, and the neutralizing antibodies elicited by the synthetic peptide 208–222 were able to confer good in vivo passive protection against homologous and heterologous EV71 strains in suckling Balb/c mice. Moreover, the monoclonal antibody generated by immunizing mice with amino acids 208–222 of VP1 showed strong neutralizing activity against EV71 in an in vitro neutralization assay. Therefore, the epitope peptide vaccine represents a promising candidate for EV71. The identification of more T-cell and B-cell epitopes of the VP1 protein, as well as a combination epitope peptide vaccine, should be considered in the search for a more effective epitope peptide vaccine.

7. Virus-like particle (VLP) vaccine

VLPs are empty particles composed of all major structural proteins, mimicking the organizations and conformations of the native particles. To date, it has been shown that a wide range of VLPs of clinically important viruses (e.g., HIV and severe acute respiratory syndrome coronavirus) induce effective neutralizing antibodies and cytotoxic T cell responses. The VLP vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is also a promising vaccine strategy for EV71.

Hu et al. and Chung et al. used a recombinant baculovirus expression system to express the 3CD and P1 proteins of EV71; the 3CD protein cleaves P1 precursor into VP1, VP3, and VP0, which spontaneously assemble to form VLPs, inducing both Th1 and Th2 immune responses. More importantly, the VLP immunization of mother mice conferred protection to neonatal mice against the lethal viral challenge, indicating EV71 VLP to be a promising vaccine. Chung et al. also found that compared with the intact VLPs, the denatured VLPs elicited significantly lower levels of neutralizing antibodies and conferred lower degrees of protection against virus challenge, which highlights the importance of preserving the conformation-dependent epitopes in preventing EV71 infection.

At present, the VLPs are mostly developed using insect cells and the strict culture conditions limit the required large scale of vaccine production. Thus, transgenic plants or yeast that can produce VLPs to be delivered by either oral administration or injection, might be promising expression systems.

8. Prospects

EV71 is one of the causative pathogens of HFMD, often complicated with neurological disorders. Due to the similarities between poliovirus and EV71 in many virological and clinical aspects, the success of the oral polio vaccine and inactivated-virus preparation in controlling poliomyelitis and eradicating the poliovirus, highlight the potential for controlling EV71 by vaccination. Poliovirus vaccine technology, both live attenuated and inactivated-virus vaccines, can be adapted to control EV71 infection.

In recent years, various types of vaccine against EV71 have been developed, but these have as yet remained at the preclinical stage. Outbreaks of EV71 have been reported around the world since 1969. In economically developed nations, it typically causes a mild illness, and most patients usually recover quickly. However, since
the late 1990s, there has been a significant increase in EV71 epidemics, and it has emerged as a serious threat to public health throughout the Asia-Pacific region. Developed countries with the resources for vaccine research and development do not view EV71 as a priority, and the vaccine industry in developed countries has little incentive to develop a vaccine for EV71. At present, there are only a few vaccine industries in the Asia-Pacific region undertaking EV71 vaccine preparation. Therefore, to effectively control EV71, more effort and cooperation worldwide is needed.

Because EV71 mainly threatens the children in developing countries, an ideal EV71 vaccine would have to be inexpensive, safe, convenient to administer, and acceptable to parents. For the inactivated vaccine virus, the established regulatory standards may allow a license to be obtained to meet the immediate demands for EV71 control. Due to the need to conserve the three-dimensional structure, the formalin-inactivated virus vaccine is a potential candidate vaccine for EV71. An oral EV71 attenuated vaccine has the potential to control EV71 in the same way as OPV controlling poliovirus, though further attenuation procedures are needed. At present, there are five genotypes of EV71. Cross-protection to the different genotypes for all the EV71 vaccines under current development is unclear. Hence, the preparation of a vaccine strain providing wide cross-protection is another important issue for EV71 vaccine development.

Conflicts of interest

There are no conflicts of interest with regard to employment, consultancy, stock ownership, honoraria, paid expert testimony, patent applications/registrations, or grants.

Funding source

We declare that we have no funding source.

Acknowledgements

We would like to express our thanks to Associate Prof. Xia Guo (The Hong Kong Polytechnic University), Dr. Zhiyong Guo (Sun Yat-sen University) and Dr. E. Mengue Mengue (Sun Yat-sen University) for their help in manuscript modification.

References

1. Ishimaru Y, Nakano S, Yamaoka K, Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child 1980; 55:383–8.
2. Schmidt NJ, Lennette HO, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129: 304–9.
3. Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, von Zeipel G. Letter: New enterovirus type associated with epidemic of aseptic meningitis and/or hand, foot, and mouth disease. J Infect Dis 1988; 158:217–27.
4. Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, von Zeipel G. Letter: New enterovirus type associated with epidemic of aseptic meningitis and/or hand, foot, and mouth disease. Lancet 1974; 1(2118).
5. Tagaya I, Takayama R, Higawara A. A large-scale epidemic of hand, foot and mouth disease associated with enterovirus 71 infection in Japan in 1978. Jpn J Med Sci Biol 1980; 33:191–6.
6. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 1982; 71:217–27.
7. Gilbert G, Dickson KE, Waters MJ, Kennett ML, Land SA, Svedson M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvment. Pediatr Infect Dis J 1987; 6:484–8.
8. Samuda GM, Chang WK, Yeung CY, Tang PS. Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Pediatr Infect Dis J 1987; 6:206–8.
9. Ho M, Chen ER, Hsu KH, Wu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:292–35.
10. Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, et al. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 2002; 46:621–7.
11. Singh S, Chow VT, Phoon MC, Chan KP, Poh CL. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol 2002; 40:2823–7.
12. World Health Organization. Outbreak news. Enterovirus, China. Wkly Epide miol Rec 2008; 83:169–70.
13. Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, et al. Enterovirus 71 outbreak in the People’s Republic of China in 2008. J Clin Microbiol 2009; 47:2351–2.
14. Ministry of health of the People’s Republic of China, Reports of National Notifiable Communicable Diseases. <http://www.moh.gov.cn/publicfiles// business/htmlfiles/zwgkty/ysjy/list.htm>.
15. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998–2005. Pediatrics 2007; 120:e244–52.
16. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003; 21:1769–75.
17. Clarke P, Ritschin N, Sourbevie F. A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaga, given as a booster to subjects primed with Avaxim. Vaccine 2001; 19:4429–33.
18. Chang LY, King CC, Hsu KH, Ning HC, Tiao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002; 109:888.
19. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JF, et al. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 2000; 7:523–8.
20. Wu CN, Liu YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001; 20:895–904.
21. Lin YC, Wu CN, Shih SR, Ho MS. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 2002; 20:2485–93.
22. Wu SC, Liu CC, Liao WC. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 2004; 22:3585–64.
23. Lin CH, Liao WC, Butler M, Wu SC. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 2007; 25:19–24.
24. Paul Y. Oral polo vaccines and their role in polo eradication in India. Expert Rev Vaccines 2009; 8:35–41.
25. John J. Role of injectable and oral polo vaccines in polo eradication. Expert Rev Vaccines 2009; 8:5–8.
26. Arita M, Shimizu H, Nagata N, Ami Y, Suzuki Y, SATA T, et al. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol 2005; 86(Pt 5):1391–401.
27. Arita M, Y一块呈现，Wakita T, Shimizu H. Cooperative effect of the attenuation determinants derived from poliovirus Sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J Virol 2008; 82:1787–97.
28. Arita M, Nagata N, Iwata N, Ami Y, Suzuki Y, Mizuta K, et al. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007; 81:9386–95.
29. Kew OM, Sutter RW, de Gouvire EW, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polo eradication. Ann Rev Microbiol 2005; 59:587–635.
30. Mamiishi S, Shahmahmoudi S, Tabatabaie H, Teimourian S, Pourakbari B, Ghesari Y, et al. Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. Eur J Pediatr 2008; 167:1335–8.
31. Edwards EA, Grant CC, Huang QS, Powell KF, Croxson MC. A case of vaccine-associated paralytic poliomyelitis. Pediatr Child Health 2000; 36:408–11.
32. The Department of Vaccines and Biologicals. Supplementary information on oral rotavirus infection. Annu Rev Microbiol 2003; 57:582–635.
33. The Department of Vaccines and Biologicals. Supplementary information on oral rotavirus infection. Annu Rev Microbiol 2003; 57:582–635.
34. The Department of Vaccines and Biologicals. Supplementary information on oral rotavirus infection. Annu Rev Microbiol 2003; 57:582–635.
41. Zhao W, Wu W, Xu X. Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against *H. pylori* infection in BALB/c mice. *Vaccine* 2007;**25**:7664–73.

42. Chen F, Zhang ZR, Yuan F, Qin X, Wang M, Huang Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. *Int J Pharm* 2008;**349**:226–33.

43. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. *Annu Rev Immunol* 2000;**18**:927–74.

44. Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. *Genet Vaccines Ther* 2007;**5**:6.

45. Cui Z, Baizer L, Mumper RJ. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. *J Biotechnol* 2003;**102**:105–15.

46. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. *Vaccine* 2007;**25**:3731–41.

47. Garmory HS, Brown KA, Titball RW. DNA vaccines: improving expression of antigens. *Genet Vaccines Ther* 2003;**1**:2.

48. Foo DG, Macary PA, Alonso S, Poh CL. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. *Viral Immunol* 2008;**21**:215–24.

49. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. *Virus Res* 2007;**125**:61–8.

50. Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. *Microbes Infect* 2007;**9**:1299–306.

51. Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, et al. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. *Biochem Biophys Res Commun* 2009;**390**:1126–8.

52. Luo L, Li Y, Cannon PM, Kim S, Kang CY. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. *Proc Natl Acad Sci U S A* 1992;**89**:10527–31.

53. Ho Y, Lin PH, Liu CY, Lee SP, Chao YC. Assembly of human severe acute respiratory syndrome coronavirus-like particles. *Biochem Biophys Res Commun* 2004;**318**:833–8.

54. Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, et al. Expression, purification and characterization of enterovirus-71 virus-like particles. *World J Gastroenterol* 2006;**12**:921–7.

55. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. *Vaccine* 2008;**26**:1855–62.